Click here to view the April 2022 edition of eNews
SOMERSET, N.J. – April 6, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction near Oxford, U.K.
Catalent plans to invest up to $160 million (£120 million) to complete the building of the facility and equip it with state-of-the-art capabilities for the development…
AMSBIO announce the addition of several new products to its growing range of magnetic bead based nucleic acid extraction kits for pathogen detection.
The MagSi-NA Pathogens MSP (Multiple Sample Pooling) kit sets a new benchmark for automated isolation of nucleic acids (RNA and DNA) from respiratory samples.
Sample pooling is useful in times of high testing and low infection prevalence where traditional sample screening methods are not cost-effective. This will be particularly effective in school and healthcare settings where periodic and comprehensive testing of large numbers of…
AMSBIO announces the launch of the QuicKey Pro™ range of ELISA kits – new easy-to-use assays that require just one step of washing, and one step of sample addition, resulting in a whole experiment taking only 90 minutes.
Compared with traditional ELISA kits, the total procedure time using a QuicKey Pro™ ELISA kit is reduced by 1-2 hours, resulting in significant gains in experimental efficiency.
Based upon proprietary Competitive and Sandwich technologies – QuicKey Pro™ ELISA assay kits allow researchers to choose the optimal ELISA format to measure their specific analyte of interest in…
AMSBIO has introduced further essential tools for SARS-CoV-2 researchers to help decipher the COVID-19 B.1.1.529 variant.
New to the AMSBIO range are recombinant proteins, easy-to-perform assay kits, Omicron pseudotyped lentiviruses and spike neutralizing antibodies for use in functional assays to block SARS-CoV-2 spike protein and ACE2 binding.
Screening for small molecule and antibody inhibitors is an important factor in assisting the discovery of treatments and vaccines for COVID-19 variants. ACE2, Spike, and the 3CL/Main protease are all potential therapeutic targets for the SARS-…
SOMERSET, N.J. – March 16, 2022 — Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the completion of a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging. The site will further expand Catalent Biologics’ global network, with early phase integrated clinical development through…
Transaction expands BioIVT’s donor network and increases its capacity to provide fresh whole blood, plasma, serum, and red blood cells for drug and diagnostic development
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Tennessee Blood Services (TBS), a commercial blood bank located in Memphis, Tennessee. TBS is FDA-registered to collect whole blood and blood products for diagnostic use by manufacturers and research facilities worldwide.
“We are delighted the TBS team is joining BioIVT and will…
Cambridge, UK 4th April 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and used.Evonetix’s novel approach to parallel DNA synthesis is underpinned by precise,…
London, Friday 1ST April 2022: Reddie & Grose LLP, the internationally renowned firm of European and United Kingdom patent, trade mark and design attorneys, has today announced a raft of promotions including the creation of two new Partners and a number of Senior Associates. These promotions, which take effect from 1 April 2022, recognise the talent and expertise in patent law across a range of market sectors, including medical devices & digital healthcare.Reddie & Grose is comprised of attorneys with specialist knowledge and expertise in biotechnology, pharmaceutical, chemical,…
Covid has put serendipitous collaboration at risk in the ‘city of ideas’
Thursday 31 March 2022, Cambridge, UK
New research has highlighted the challenge of maintaining innovation-fuelled growth in the new hybrid working environment.
A survey of current working practices carried out by Cambridge Ahead – a membership organisation of nearly 50 major employers in the city – found widespread concern that hybrid working has reduced the opportunities for people to connect beyond their immediate team. Collaboration between teams and with other organisations was more likely to have worsened than…